Screener
AngioDynamics ANGO Q1 2027 Annual earnings
Reported October 8, 2026 · Before market open
Revenue$80.9MBeat by $404.8K
EPS-$0.04Beat by $0.07
Revenue estimate$80.5M
EPS estimate-$0.11
“Our first quarter results reflect the continued, consistent execution we've built into this business. Med Tech again led our growth, highlighted by Auryon's 21st consecutive quarter of double-digit atherectomy growth, continued performance in Mechanical Thrombectomy, and ongoing strength in our NanoKnife oncology platform. We remain focused on the fundamentals that have driven our performance over the past several years, and we're confident in our ability to deliver on the outlook we've laid out for fiscal 2027.”
Next report
Jan 6, 2027 (in 2 months)Revenue estimate$84.3M
EPS estimate-$0.11
Valuation & ratios
Segments
By product
Versus estimates
Revenue
Diluted EPS
FAQ
- When did AngioDynamics report Q1 2027 earnings?
- AngioDynamics (ANGO) reported Q1 2027 earnings on October 8, 2026 before market open.
- What were AngioDynamics's Q1 2027 revenue and EPS?
- AngioDynamics reported revenue of $80.9M and eps of $-0.04 for Q1 2027.
- Did AngioDynamics beat estimates in Q1 2027?
- Revenue beat the consensus estimate of $80.5M by $404.8K. EPS beat the consensus estimate of $-0.11 by $0.07.
- How did AngioDynamics's Q1 2027 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 6.9% from $75.7M a year earlier and eps grew 60.0% from $-0.10.
- Where can I find AngioDynamics's Q1 2027 SEC filings?
- You can read the 8-K earnings release (0001140361-26-039019) and the 10-K/A periodic report (0001140361-26-037943) directly on SEC EDGAR. The filing index links above go to sec.gov.
